Monte Rosa Therapeutics Total Liabilities

Monte Rosa Therapeutics (GLUE) currently reports a total liabilities of $210M as of June 2026. That compares with $92M in the prior-year period — up 130.6% year over year. Use the charts on this page to explore Monte Rosa Therapeutics's total liabilities history and peer comparisons.

Monte Rosa Therapeutics's total liabilities increased from $92M to $210M — a 130.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monte Rosa Therapeutics reported $210M in total liabilities as of June 2026. That compares with $92M in the prior-year period — up 130.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monte Rosa Therapeutics, and consider following GLUE for alerts when major investors trade the stock.

Monte Rosa Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLUE with unrelated industries.